Showing 1 to 2 of 2 results


Eli Lilly CEO Calls UK "Worst in Europe" for Drug Prices, Threatening Investment
Eli Lilly's CEO, Dave Ricks, criticized the UK's drug pricing regime as the "worst in Europe," citing it as a reason for the pharmaceutical industry's withdrawal of nearly £2 billion in planned investments.
Eli Lilly CEO Calls UK "Worst in Europe" for Drug Prices, Threatening Investment
Eli Lilly's CEO, Dave Ricks, criticized the UK's drug pricing regime as the "worst in Europe," citing it as a reason for the pharmaceutical industry's withdrawal of nearly £2 billion in planned investments.
Progress
56% Bias Score

UK Drug Pricing Dispute: NHS Faces Industry Backlash Over Clawback Scheme
The UK government and pharmaceutical companies failed to agree on NHS drug pricing by a Friday deadline, resulting in the continuation of a drug price clawback scheme at a rate the industry deems unsustainable, potentially affecting patient access to new medicines and the UK's life sciences sector.

UK Drug Pricing Dispute: NHS Faces Industry Backlash Over Clawback Scheme
The UK government and pharmaceutical companies failed to agree on NHS drug pricing by a Friday deadline, resulting in the continuation of a drug price clawback scheme at a rate the industry deems unsustainable, potentially affecting patient access to new medicines and the UK's life sciences sector.
Progress
56% Bias Score
Showing 1 to 2 of 2 results